Related Experiment Video
Updated: Feb 12, 2026

P50 Sensory Gating in Infants
Published on: December 26, 2013
A Case Report of 2 Sirolimus-Related Deaths Among Infants With Kaposiform Hemangioendotheliomas
Hanru Ying1, Congzhen Qiao1, Xi Yang1
1Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital and School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Abstract:
Kaposiform hemangioendothelioma (KHE) is a rare infiltrative vascular tumor that is potentially life-threatening when presenting with Kasabach-Merritt phenomenon (KMP). KMP is clinically characterized as severe thrombocytopenia and hypofibrinogenemia and therefore is associated with a high mortality rate. There is no standard of cure for KHE currently. Potential medications, including corticosteroids, propranolol, and chemotherapy drugs such as sirolimus, are often used for alleviating KHE symptoms. Although some case reports of sirolimus treatment have shown promising results with recovered coagulant parameters, the off-target effects may cause severe problems. Here we describe 2 cases of infant patients with KHE and KMP who were scheduled to receive sirolimus on a long-term basis. However, both patients developed paroxysmal cough and tachypnea shortly after the onset of sirolimus treatment and succumbed to infection thereafter. This report reveals a potential risk of infection in sirolimus-treated infant patients. The fatal complication highlights the importance of antibiotic prophylaxis and serum sirolimus level monitoring to ensure the safe use of sirolimus in the treatment of infant patients with KHE.
Insights
Kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon (KMP) in infants can be fatal. Sirolimus treatment may increase infection risk, necessitating careful monitoring and antibiotic prophylaxis.
Area of Science:
- Pediatric Oncology
- Vascular Malformations
- Pharmacology
Background:
- Kaposiform hemangioendothelioma (KHE) is a rare, aggressive vascular tumor.
- Kasabach-Merritt phenomenon (KMP) associated with KHE presents with severe thrombocytopenia and hypofibrinogenemia, leading to high mortality.
- Current KHE treatments lack standardization, with medications like sirolimus showing potential but carrying risks.
Observation:
- Two infant patients with KHE and KMP were treated with sirolimus.
- Both patients developed respiratory complications (cough, tachypnea) shortly after sirolimus initiation.
- These complications led to fatal infections in both cases.
Findings:
- Sirolimus treatment in infants with KHE and KMP may be associated with an increased risk of severe infections.
- Respiratory symptoms like cough and tachypnea can be early indicators of infection in these patients.
- Fatal outcomes underscore the potential dangers of sirolimus's off-target effects.
Implications:
- The findings highlight the critical need for vigilant monitoring of sirolimus-treated infants for signs of infection.
- Prophylactic antibiotics should be strongly considered in this patient population.
- Regular monitoring of serum sirolimus levels is crucial for optimizing treatment safety and efficacy.
Related Concept Videos
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Drug Dosing: Infants and Children
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...

